
Adrelia Allen/LinkedIn
Jun 7, 2025, 12:30
Adrelia Allen: ASCO25 Highlights – Meaningful Discussions on Clinical Trial Diversity
Adrelia Allen, Executive Director, Clinical Trial Patient Diversity at Merck, shared a post on LinkedIn:
“At ASCO25, I was inspired by the meaningful dialogue shared by a dedicated group of oncology leaders and advocates who came together to discuss how we can expand access and representation in clinical trials.
A special thank you to my colleague Marjorie Green for opening the session with a clear call to action: our clinical trials must reflect the populations our medicines and vaccines are designed to help. Representation in research isn’t just a moral imperative – it’s essential to building trust, advancing science and accelerating access to care that truly meets the needs of people with cancer.
Grateful to the panelists and moderator M. Catherine Pietanza for their valuable insights and continued leadership:
– Rob Winn – VCU Massey Comprehensive Cancer Center
– Nadine Barrett – Wake Forest School of Medicine
– Ruben Mesa – Atrium Health Levine Cancer Center
– Camille (Pope) Campbell – AcclinateLastly, thank you to A. Amanda Bishop and Michelle Chawla for bringing this conversation to ASCO25.”
Read OncoDaily’s Special Articles from ASCO25:
Highlights from ASCO 2025 Day 1
Highlights from ASCO 2025 Day 2
Highlights from ASCO 2025 Day 3
Highlights from ASCO 2025 Day 4
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 29, 2025, 17:43
Jun 29, 2025, 17:22
Jun 29, 2025, 17:04
Jun 29, 2025, 16:44